All In Biotech

Drug Trial Radar · NCT00144768

A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients

A Multicenter, Multinational, Open-Label Study of Anti-Laronidase Antibody Formation and Urinary GAG Levels in Patients With Mucopolysaccharidosis I (MPS I) Being Treated With Aldurazyme® (Laronidase).

Last checked: Nov 20, 2026Latest source record: May 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Planned (sponsor's estimate)

Start

Jul 2004

Primary completion

May 2007

Study completion May 2007

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
Collaborators
BioMarin/Genzyme LLC
First posted
Sep 5, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether the development of antibodies to laronidase in patients with MPS I receiving Aldurazyme® impairs the clearance of GAG substrate.

Conditions

  • Mucopolysaccharidosis I
  • Hurler's Syndrome
  • Hurler-Scheie Syndrome
  • Scheie's Syndrome

Interventions

  • laronidaseDrug

    dose of 0.58mg/kg body weight IV every week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Urinary GAG (glycosaminoglycans)Time frame: Up to 4 years
  2. Immunogenicity TestingTime frame: Up to 4 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Childrens Hospital Los Angeles

    Los Angles, California

  • Connecticut Children's Medical Center

    Hartford, Connecticut

  • Children's Hospital of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.